anti-HBs 10.4: does it count as protection?
What a borderline anti-HBs value means, why vaccine immunity differs from recovery, and when to repeat the test.
Source-backed
A small nodule on screening is not a cancer diagnosis; what a normal AFP and FibroScan do and do not mean, and how contrast imaging, short-interval follow-up, and surveillance are arranged.
When a liver cancer screening ultrasound reports a small nodule, a low-echo area, or a lesion, it is easy to hear bad news. But screening is designed to find suspicious findings in people without symptoms, not to make a diagnosis. Most small findings need a second imaging step to characterise them, and many turn out to be benign or an imaging artifact.
What decides the next step is not the word in the report but the size, position, margins, and ultrasound visibility of the finding, plus your own risk factors such as cirrhosis and family history of liver cancer.
Ultrasound depends heavily on the operator. Obesity, fatty liver, bowel gas, rib shadowing, and breathing can all affect image quality. The same lesion can be described as low-echo, high-echo, or ill-defined on different machines and from different angles.
So a nodule on ultrasound is a clue, not a verdict. It may be a real lesion, a vessel cross-section, uneven fat distribution, a fibrosis nodule, or an artifact, and contrast imaging or short-interval follow-up is what separates them.
AFP is a blood marker commonly used in liver cancer screening, but it is neither sensitive nor specific enough on its own. Some people with liver cancer never have a raised AFP, and AFP can rise with hepatitis activity, cirrhosis, or other causes.
So a normal AFP does not rule out liver cancer, and a raised AFP does not confirm it. It has to be read with ultrasound, contrast imaging, and your risk background, never as a single number to relax or panic over.
FibroScan measures liver stiffness and fat content to estimate fibrosis and cirrhosis risk and to decide which follow-up group you are in. It is not designed to find or exclude a liver nodule.
A good FibroScan result is reassuring about cirrhosis risk, but it does not cancel a nodule seen on ultrasound. The two tests answer different questions.
For a suspicious small nodule, clinicians usually arrange multiphase contrast CT or contrast MRI, or contrast ultrasound when available, to see how the lesion enhances in the arterial, portal venous, and delayed phases, and to classify it with a system such as LI-RADS. Sometimes short-interval follow-up is arranged first to watch size and shape.
If the nodule is very small or poorly seen on ultrasound, contrast MRI or follow-up may come first. The important thing is to complete whatever is scheduled on time. Do not delay out of fear, and do not order a pile of duplicate tests on your own.
People with chronic hepatitis B and no nodules usually have ultrasound plus AFP about every 6 months, with the exact interval set by the clinician based on cirrhosis, family history, age, and previous results.
After a nodule is found, the rhythm changes temporarily: a repeat scan in about 3 months, or contrast imaging straight away. Once the nature of the nodule is clear, routine surveillance resumes. Record each date and conclusion so the trend is visible at follow-up.
Keep the ultrasound report, AFP, FibroScan, previous imaging, and lab results together. Ask for the size, position, and next imaging step. Complete the contrast imaging or repeat scan on the date your clinician sets. Do not cancel follow-up because AFP is normal, and do not decide on your own that it is nothing. Seek care promptly for jaundice, abdominal pain, swelling, weight loss, or fever.
Screening and evaluation of abnormal findings
AASLD HCC guidance recommends ultrasound plus AFP for high-risk groups and further contrast imaging for abnormal findings.
Liver cancer screening recommendations
Hepatitis B Foundation patient resources explain the roles and limits of ultrasound and AFP, and that abnormal results need further testing.
Surveillance and follow-up
CDC hepatitis B surveillance guidance describes regular liver cancer surveillance according to risk.
Liver cancer surveillance
WHO 2024 chronic hepatitis B guidance recommends periodic surveillance for high-risk groups such as people with cirrhosis.
Treatment and monitoring principles
AASLD guidance individualises follow-up and surveillance using cirrhosis, age, and family history.
What a borderline anti-HBs value means, why vaccine immunity differs from recovery, and when to repeat the test.
HBeAg loss is not the same as anti-HBe seroconversion or a functional cure, and HBeAg-negative hepatitis can still be active.
Why hepatitis D depends on hepatitis B, which HBsAg-positive people should ask about HDV testing, and what to do after a positive or high-risk result.